(Q36973572)

17 August 2017

1 reference

title

Preoperative chemotherapy treatment of breast cancer--a review (English)

1 reference

17 August 2017

1 reference

Aman U Buzdar

1

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

110

1 reference

17 August 2017

issue

11

1 reference

17 August 2017

page(s)

2394-2407

1 reference

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

The biology of neoadjuvant chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Neoadjuvant chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Processing and Evaluation of Breast Excision Specimens: A Clinically Oriented Approach

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Hand-foot syndrome after dose-dense adjuvant chemotherapy for breast cancer: a case series

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAK

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Multimodal-therapy breast salvage in the urban poor with locally advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Concomitant versus sequential chemotherapy in the treatment of early-stage and metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Epothilone A and B—Novel 16-Membered Macrolides with Cytotoxic Activity: Isolation, Crystal Structure, and Conformation in Solution

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Epothilone B and its analogs - a new family of anticancer agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

The biology and medicinal chemistry of epothilones

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

EPO906 (epothilone B): a promising novel microtubule stabilizer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23083

7 January 2021

Identifiers

DOI

10.1002/CNCR.23083

1 reference

17 August 2017

1 reference